Last reviewed · How we verify

NCT05903430: MIDSECTION

A Feasibility Study of MRI Guided Stereotactic Ablative Radiotherapy (MIDSECTION)

Recruiting now Last updated 5 September 2025
What this trial tests

trial in Abdominal Cancer in 60 participants. Currently enrolling.

Timeline
29 August 2025
Primary endpoint
29 January 2027
29 January 2027

Quick facts

Lead sponsorThe Christie NHS Foundation Trust
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment60
Start date29 August 2025
Primary completion29 January 2027
Estimated completion29 January 2027
Sites1 location across United Kingdom

Conditions studied

Sponsor

The Christie NHS Foundation Trust

Who can join

18 and older, any sex, with Abdominal Cancer or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine if the investigators are able to deliver highly focused, intense radiation to tumours in the abdominal region or chest cavity whilst limiting the dose to surrounding organs using a high field strength MR-Linac.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Harnessing the Power of Radiotherapy for Lung Cancer: A Narrative Review of the Evolving Role of Magnetic Resonance Imaging Guidance.
    Cheng SH, Lee SY, Lee HH. · · 2024 · cited 3× · PMID 39123438 · DOI 10.3390/cancers16152710

Verify or expand the search:

Other recruiting trials for Abdominal Cancer

Currently open trials in the same condition.

Other The Christie NHS Foundation Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05903430.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing